The organic cation transporter 1, encoded by the SLC22A1 gene, is responsible for the uptake of the anti-hyperglycaemic drug, metformin, in the hepatocyte. We assessed whether a genetic variation in the SLC22A1 gene is associated with the glucose-lowering effect of metformin. Incident metformin users in the Rotterdam Study, whose HbA1c measurements were available, were identified. Associations between 11 tagging single nucleotide polymorphisms in the SLC22A1 gene and change in the HbA1c level were analyzed. A total of 102 incident metformin users were included in this study sample. Except for the rs622342 A4C polymorphism, no significant differences in metformin response were observed. For each minor C allele at rs622342, the reduction in HbA1c levels was 0.28% less (95% CI 0.09-0.47, P ¼ 0.005). After Bonferroni correction, the P-value was 0.050. To conclude, genetic variation at rs622342 in the SLC22A1 gene was associated with the glucose-lowering effect of metformin in patients with diabetes mellitus.
Introduction
Metformin is an oral anti-hyperglycaemic drug, widely used in the treatment of diabetes mellitus type 2. The major mode of action is to reduce hepatic glucose production, although the exact pharmacological action has not yet been fully determined. 1, 2 Besides, metformin also increases the insulin responsiveness of skeletal muscles. 3 The main route of elimination is through tubular renal secretion.
Metformin is actively transported across membranes. The organic cation transporter 1 (OCT1) is responsible for uptake in hepatocytes, which is an essential step in reducing hepatic glucose production. 4 In OCT1 gene knockout mice, the liver concentration of metformin was 30 times lower than that in mice with normal functioning OCT1 transporters. Furthermore, metformin blood concentrations were higher, whereas the glucose-lowering effect decreased. [5] [6] [7] In humans, OCT1 is encoded by the SLC22A1 gene located at chromosome 6q25.3. 8 Controversy exists as to whether polymorphisms in this gene are associated with the glucose-lowering effect of metformin. 9 In a study of 20 healthy Caucasian volunteers, differences in metformin blood concentrations and glucose levels after an oral glucose tolerance test were found between individuals with a reduced function allele (coding for the amino acid changes R61C, G401S, M420del and G465R) in the SLC22A1 gene and those without. 5, 10 However, in a study of 33 Japanese diabetes mellitus patients comparing responders and nonresponders to metformin, no differences in allele frequencies were found. 11 In this prospective population-based cohort study, we studied the association between tagging single nucleotide polymorphisms (SNPs) in the SLC22A1 gene and metformin response in Caucasian patients with diabetes mellitus.
Results
In the Rotterdam Study, we identified 152 patients with diabetes mellitus who had a first prescription for metformin between 1 April 1997 and 1 January 2008, and for whom an HbA1c measurement in the period of 30 days before and in the period between 14 and 100 days after the start of metformin therapy was available. Eight patients were excluded because they were prescribed rosiglitazone (one patient), pioglitazone (one patient) or insulin (six patients) at the time of HbA1c measurement before the start of metformin therapy. In 24 patients, no blood sample was available for genotyping. Eighteen patients discontinued metformin therapy before the first HbA1c measurement after start (16 patients) (DDD) . In 12 of the 102 patients (11.8%), the prescribed daily dose was changed between the first prescription and the first measurement of HbA1c. In 11 patients, the prescribed daily dose was increased, and in one patient it was decreased. Sulfonylurea had been prescribed in 60 participants before the start of metformin therapy (average 1.29 DDD), and in 49 participants after the start of metformin therapy (average 1.33 DDD).
Twelve tagging polymorphisms in the SLC22A1 gene were analyzed ( Table 2 ). All genotype distributions were in Hardy-Weinberg equilibrium. The SNP, rs3798168, was excluded from the analyses, because the minor allele frequency was 0.02. The SNPs, rs1443844 and rs2297374, were in linkage disequilibrium (r 2 ¼ 0.89, D 0 ¼ 1.00), whereas the other SNPs were not (r 2 o0.8). A statistically significant association (P ¼ 0.005) was found between SNP rs622342 and change in the HbA1c level, leading to an average of 0.28% less decrease in HbA1c levels for each minor C allele (95% CI 0.09-0.47; P ¼ 0.0050) ( Table 3 ). After Bonferroni correction for multiple testing, the P-value for this association was 0.050. For the other tagging SNPs, no significant associations with change in the HbA1c level were found. Participants with the AA genotype at rs622342 had an average decrease of 0.53% in the HbA1c level, whereas in participants with the AC genotype, the average decrease was 0.32%, and in participants with the CC genotype, the HbA1c level increased on an average with 0.02% (Table 4) . After adjustment for cofactors, the difference in HbA1c decrease between patients with the AC and those with the AA genotype was 0.29% (95% CI 0.002-0.58, P ¼ 0.049). The difference between patients with the CC and those with the Genotyping failed in some participants. Therefore, not all numbers add up to 102.
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AA genotype was 0.58% (95% CI 0.22-0.93, P ¼ 0.002). No differences were found between rs622342 genotypes in baseline HbA1c levels (P ¼ 0.58), between prescribed doses of metformin (P ¼ 0.41) or between changes in prescribed doses of sulfonylurea (P ¼ 0.59). The rs622342 genotypes did not differ significantly in frequency between patients who continued metformin and those who discontinued metformin or started acarbose, rosiglitazone, pioglitazone or insulin therapy (w 2 ¼ 3.51, P ¼ 0.17).
Discussion
In this population-based cohort study, the SNP, rs622342, was associated with differences in HbA1c reduction in diabetes mellitus patients using metformin. The HbA1c levels represent glycaemic control in the preceding period of time, and are therefore a stable measurement of metformin response and a better outcome measure in a populationbased setting than is serum glucose. The decrease in HbA1c level in patients with the AC genotype who were started on metformin therapy was 0.29% less than that in patients with the AA genotype. In patients with the CC genotype, the decrease in HbA1c level was 0.58% less than that in patients with the AA genotype. In patients with the CC genotype, the HbA1c levels increased by 0.02% after start of metformin therapy. Most likely, patients with the AC or CC genotype have less OCT1 transporter activity, and their capacity to transport metformin into hepatocytes is reduced. As a consequence, the glucose-and HbA1c level-lowering effect of metformin is impaired. The HbA1c level is expressed as the proportion of haemoglobin that is glycosylated, and is a marker for the average glucose levels in the preceding period of time. The average life span of erythrocytes incorporating haemoglobin is 90 days, and the HbA1c level represents the average glucose level in the preceding 90 days, although it mainly reflects the preceding 2-4 weeks before measurement. In this study, we choose to include all HbA1c levels from 14 days after the start of metformin therapy. Physicians measured the HbA1c levels between 14 and 30 days after the start of metformin therapy in 21 of the 102 participants in this study. Although the effect of metformin therapy is not completely established at that time, the HbA1c level gives an indication of the change in glucose level, and physicians most likely adjust therapy according to these results. Not including this first measurement will probably introduce bias because of the changes in therapy, such as discontinuing metformin therapy or switching to other anti-diabetic drugs. If we selected the first HbA1c measurements in the time period between 30 and 120 days after the start of metformin therapy, we found a tendency towards more discontinuations of metformin and switches to acarbose, pioglitazone, rosiglitazone or insulin in users with the A allele. In the group of incident users with the AA genotype, 23% (n ¼ 14) discontinued metformin therapy or switched to acarbose, pioglitazone, rosiglitazone or insulin, versus 15% (n ¼ 9) in users with the AC genotype and 0% in users with the CC genotype (w 2 ¼ 4.94, P ¼ 0.085). In the patient files of general practitioners, we were able to find the reason for stopping or switching in seven of the 23 cases. In five cases, the reason for stopping or switching was an adverse drug reaction; in one case, a sufficient regulation without drug therapy; and in another case, insufficient regulation with oral anti-diabetic drugs. The adverse drug reactions identified were malaise, nausea, itching, decreased appetite and diarrhoea. These results may suggest that incident metformin users with an AA genotype have more problems with adverse effects due to metformin therapy.
The average decrease in the HbA1c level (0.4%) is rather low. A possible explanation is that, after an average of 52 days, the decrease in HbA1c is not completely established. Another explanation is that the average prescribed dose of metformin (677 mg) is lower than that recommended in guidelines. The guidelines recommend an initial daily dose of 1500-2000 mg, and this dose may be increased after We corrected for 10 independent tests, because the minor allele frequency of one tagging SNP was below 0.05 and two tagging SNPs were in linkage disquilibrium. Genetic variation in OCT1 and metformin ML Becker et al 10-15 days to, at the most, 3000 mg a day. The reason for the low doses of metformin used in this study may be that the average age of the study population is 77 years, and physicians are cautious when they prescribe high doses of metformin in this elderly population because of the fear of potential adverse effects.
In our study, we used twelve tagging SNPs, different from the SNPs used in the study by Shu et al.
5,10 As we are not aware of studies genotyping both the coding SNPs and the tagging SNPs, we do not know whether these SNPs are in linkage disequilibrium with each other. The SNP, rs622342, associated in this study with the glucose-lowering effect of metformin, is located between exon 8 and exon 9 ( Figure 1 ). The SNPs studied by Shu et al. were all situated in exons resulting in amino acid changes and were identified in in vitro studies. With the use of tagging SNPs in this study, we could analyze both SNPs in introns and in exons, not necessarily resulting in amino acid changes. Besides changes in amino acid sequence, SNPs may also affect gene expression, resulting in increased or decreased transporter functioning. With the use of tagging SNPs, we could identify other SNPs associated with metformin response.
In population-based studies, bias may affect results. We believe that bias in our study is minimal. The HbA1c measurements in this study were part of regular daily practice. Bias may have occurred if discontinuation of metformin therapy was associated with genotype. For the rs622342 polymorphism, no differences in genotype frequency were found between patients who continued or discontinued metformin therapy in the time period used in this study. Participants in this study were co-prescribed sulfonylurea before and after the start of metformin therapy. As the polymorphisms in the OCT1 gene do not affect sulfonylurea therapy, the changes in prescribed doses are random. Moreover, in our analyses, we adjusted for change in the prescribed dose of sulfonylurea. If there were differences in prescribed doses, patients with a low response to metformin would receive higher prescribed doses of sulfonylurea, and this would underestimate the effects of the OCT1 polymorphism. No differences in time to the first HbA1c measurement after start were seen, and therefore it is unlikely that there were differences in the frequency of HbA1c measurement between genotypes, influencing the effect size found in this study. We identified all incident metformin users in the Rotterdam Study and information was collected prospectively, without earlier knowledge of the study hypothesis. The permission of patients to take blood and isolate DNA for scientific research was most likely independent from the genotype we studied. In this study, we analyzed 11 SNPs in the SLC22A1 gene, and therefore multiple testing may play a role. To cope with this, we adjusted the cutoff for 10 independent SNPs using Bonferroni correction, which gave a P-value of 0.050. Two SNPs were in strong linkage disequilibrium and were therefore counted as one independent test. The Bonferroni test assumes an independence between SNPs. In our study, there was some linkage disequilibrium among many SNPs, and therefore the Bonferroni test is a conservative test, underestimating the significance of the association. Nevertheless, replication of our results in a prospective observational study or trial is warranted.
To conclude, in this population-based cohort study, we found an association between genetic variation in the gene encoding the OCT1 transporter protein and glucose reduction by metformin in diabetes mellitus patients. Metformin therapy is less effective in reducing glucose and HbA1c levels in diabetes mellitus patients carrying the minor C allele at SNP rs622342 than it is in wild-type AA patients. This information could be clinically relevant to predict the glucose-lowering effect of metformin before start of therapy.
Materials and methods
Setting
Data for these analyses were obtained from the Rotterdam Study, a prospective population-based cohort study of 7983 Caucasians aged 55 years and older in the suburb of Ommoord in Rotterdam. Participants were invited between 1990 and 1993 and have been continuously followed up since then. All participants of the Rotterdam Study gave written informed consent. Ethical approval was obtained from the Medical Ethical Committee of the Erasmus MC. The aim of this study was to investigate the determinants of chronic and disabling cardiovascular, neurodegenerative, locomotor, endocrine and ophthalmological diseases. The rationale, ethical approval and design of this study have been described before. 12, 13 The seven pharmacies in Ommoord dispensed the prescriptions of more than 99% of all participants. Information on all filled prescriptions from 1 January 1991 until 1 January 2008 was available, and included the product name of the drug, the anatomical therapeutical chemical code, the amount dispensed, the prescribed dosage regimen and the date of dispensing.
14 For this study, we used the HbA1c assessments from the 'Stichting Trombosedienst en Artsenlaboratorium Rijnmond-Medisch Diagnostisch Centrum' (STAR-MDC), which performs all outpatient laboratory assessments for general practitioners in the Rijnmond area of Rotterdam with a potential source population of more than 1 million inhabitants. Hereby, we obtained all outpatient HbA1c assessments from all participants between 1 April 1997, the time at which a new computer system was introduced at STAR-MDC, and 1 January 2008.
Study sample
All participants in the Rotterdam Study, who were incident metformin users in the period between 1 April 1997 and 1 January 2008, were included in this analysis. Incident metformin use was defined as a first-dispensed prescription for metformin in the database, which included all prescriptions from 1 January 1991 onwards. The study sample consisted of all incident metformin users who had both a measurement of HbA1c in the period of 30 days before the first prescription of metformin and in the period between 14 and 100 days after the first prescription of metformin. Patients who discontinued metformin therapy before the first measurement after start were excluded. We also excluded patients who were co-prescribed acarbose, rosiglitazone, pioglitazone or insulin at the time of one of the two HbA1c measurements, because DDD for these drugs are not comparable with each other, and these patients most likely differ in their severity of disease. Patients using sulfonylurea were not excluded.
Outcomes
The goal of anti-hyperglycaemic therapy is to reduce plasma glucose levels. The HbA1c level is the percentage of haemoglobin in the blood that is glycosylated and represents the average glucose level in the preceding period of time. As the HbA1c level is a more stable measurement of glycaemic control than are plasma glucose levels, HbA1c levels are used more frequently for long-term therapeutic purposes. We analyzed the association between genetic variation in the SLC22A1 gene and difference in HbA1c level between the last HbA1c measurement before start of metformin therapy and the first HbA1c measurement after start. The target level for diabetes mellitus patients is an HbA1c level below 7%. 15 
Cofactors
Characteristics considered as potential determinants affecting the change in HbA1c level were age, gender, the HbA1c level at the last measurement before start of metformin, the daily prescribed dose of metformin at the time of the first measurement after start and the change in the daily prescribed dose of sulfonylurea. To make the prescribed doses of different sulfonylurea comparable with each other, we divided the prescribed daily dose by DDD.
14 The DDD is a standardized dosing measure representing the recommended daily dose for the main indication in an adult.
Genotyping
In this study, we used a selection of tagging SNPs on the Illumina 550k SNP array (Illumina Inc., San Diego, CA, USA) for genotyping, according to the manufacturer's instruction. Quality controls and results of genotyping were described earlier. 16 The tagging SNPs on the array were selected using an algorithm with which, in a Caucasian population, 90% of all phase I and II Hapmap SNPs are covered by at least one SNP on the array. 8, 17, 18 This coverage arises because genetic variation is transmitted in blocks, in which haplotype alleles exist. Within these haplotypes, variant alleles are associated with each other. This more frequent occurrence of combinations of variant alleles than that expected from a random formation is called linkage disequilibrium. For this study, we selected the tagging SNPs in the SLC22A1 gene that were on the array. SNPs with a minor allele frequency lower than 0.05 were excluded, because the power of this study was too low to find significant associations for these SNPs.
Statistical analysis
Deviations from the Hardy-Weinberg equilibrium and differences in genotypes between patients who continued and discontinued metformin therapy were analyzed using w 2 -tests, and differences in baseline HbA1c levels, prescribed doses of metformin and change in prescribed doses of sulfonylurea were analyzed using one-way analysis of variance (ANOVA). Multivariate linear regression was used to analyze the differences in HbA1c change between genotypes. For each polymorphism, we calculated the association between the number of variant alleles and the difference in HbA1c change. For polymorphisms significant in this analysis, we calculated the difference in HbA1c change between Aa and AA and between aa and AA, in which A represents the more common allele and a the minor allele. These analyses were carried out with SPSS software (version 15.0; SPSS, Chicago, IL, USA).
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